

ELCC 2021 VIRTUAL INDUSTRY SATELLITE SYMPOSIUM

Immuno-Oncology Treatment Paradigms for First-Line ES-SCLC and Unresectable Stage III NSCLC

Thursday 25 March 2021 (Channel 1)
16:10–17:40 (CET)

All recordings will be available for on-demand viewing until Tuesday 30 March 2021

The Treatment Paradigm for Unresectable Stage III NSCLC – Exploring the Growing Evidence Base

Maya Gottfried

Treating Unresectable Stage III NSCLC with Immuno-Oncology: A Clinical Case Study

Martin Reck

The Evolving Role of Immuno-Oncology Treatment for ES-SCLC

Eduarne Arriola Aperribay

Treating 1L ES-SCLC with Immuno-Oncology: A Clinical Case Study

Alfredo Addeo

Live Panel Discussion and Audience Q&A

Moderated by Martin Reck



Martin Reck (Chair)

LungenClinic
Grosshansdorf,
Großhansdorf, Germany



Alfredo Addeo

Hôpitaux Universitaires
de Genève, Geneva,
Switzerland



Eduarne Arriola Aperribay

Hospital del Mar,
Barcelona, Spain



Maya Gottfried

Meir Medical Center,
Kfar Saba, Israel

AstraZeneca's Commitment to Sustainability



\$15.5 million

invested in
environmental
efficiency projects in
2019 (NRRGG fund)



CPD A Lists

One of three companies
worldwide to achieve
double A listing for
Climate Change and
Water Security for four
consecutive years



62% of our power

is sourced or
generated from
renewable sources



100% of API

(Active Pharmaceutical
Ingredient) discharges
from AstraZeneca sites
were assessed as safe



18% reduction

in our water use
since 2015



**25% of our
vehicles**

in Europe, North
America or Japan are
hybrid or electric



AstraZeneca is investing up to \$1 billion in a commitment to become carbon neutral by 2025 and carbon negative by 2030. Find out more about AstraZeneca's commitment to sustainability at our website.